Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly, +61

The Lancet Oncology

Carboplatin-based DoubletMedicineMetronomic TherapyGynecologyPlatinum-sensitive Ovarian Cancer +5

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa, +31

The Lancet

Advanced Cervical CancerCervical Cancer ManagementCervical CancerMedicineGynecology +8

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley, +328

The Lancet Oncology

Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line Treatment +7

Building clinical trials around patients: Evaluation and comparison of decentralized and conventional site models in patients with low back pain

Carsten Sommer, Diego Zuccolin, Valdo Arnera, +5

Contemporary Clinical Trials Communications

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).

Andreas du Bois, Anne Floquet, Jae‐Weon Kim, +16

Journal of Clinical Oncology

Cancer PharmacologyGynecologyPathologyPharmacotherapyGynecology Oncology +16

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk, +16

JAMA Oncology

Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)

Richard T. Penson, Ricardo Villalobos-Valencia, Nicoletta Colombo, +13

Gynecologic Oncology

Olaparib MonotherapyMedicineCancer ManagementPhase Iii TrialGynecology +7

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Liselore Loverix, Ignace Vergote, Pieter Busschaert, +22

European Journal of Cancer

MedicineClinical TrialsGynecologyPharmacotherapyCancer Treatment +9

Aggressive angiomyxoma of the vulva

Raffaella Ribaldone, Paola Piantanida, Daniela Surico, +3

Gynecologic Oncology

Vulvar DiseasesSurgical PathologyVascular MalformationGynecologyVascular Surgery +4

The Work Place Educational Climate in Gynecological Oncology Fellowships Across Europe

Jurgen M.J. Piek, Michaela Bossart, Klarke Boor, +9

International Journal of Gynecological Cancer